Compare RBBN & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | IPSC |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 407.6M |
| IPO Year | 2017 | 2021 |
| Metric | RBBN | IPSC |
|---|---|---|
| Price | $3.05 | $2.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $4.67 | $4.25 |
| AVG Volume (30 Days) | ★ 1.0M | 714.4K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | 91.30 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $1.83 | $0.44 |
| 52 Week High | $4.29 | $2.97 |
| Indicator | RBBN | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 66.02 | 56.65 |
| Support Level | $2.72 | $2.13 |
| Resistance Level | $3.09 | $2.67 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 76.19 | 76.54 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.